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Natriuretic peptides (NPs) comprise a family of vasoactive
hormones that play important roles in the regulation of car-
diovascular and renal homeostasis. Along this line, atrial NP
(ANP) (international non-proprietary name: carperitide,
HANP) is an approved drug for the treatment of acute heart
failure. In recent years, evidence has been given that the NP
system possesses a far broader biological spectrum than the
regulation of blood pressure and volume homeostasis. In fact,
a substantial amount of in vitro work indicates that ANP af-
fects important inflammatory processes and signaling path-
ways. Quite surprisingly, however, no information exists on
the in vivo antiinflammatory potential and signaling of ANP.
We show here that pretreatment of lipopolysaccharide (Sal-
monella abortus equi, 2.5 mg/kg)-challengedmice with ANP (5
g/kg iv, 15 min) rapidly inhibits nuclear factor-B activation
via inhibition of phosphorylation and degradation of the
IB- protein. ANP also reduces Akt activation upon lipopoly-
saccharide injection. In ANP-pretreated mice, the increase of
TNF- serum concentration is markedly prevented; most im-
portantly, the survival of these animals improved. These find-
ings demonstrate both in vitro and in vivo an antiinflamma-
tory profile of ANP that deserves to be further investigated in
a therapeutic perspective. (Endocrinology 148: 332–336, 2007)
WHEN LIPOPOLYSACCHARIDE (LPS), a major con-stituent of the outer membrane of Gram-negative
bacteria, crosses the natural barriers of the body and reaches
the systemic circulation, it might give rise to a systemic
inflammatory response (1). The induction of proinflamma-
tory gene expression by LPS is an important aspect in the
immunopathological features of LPS-induced shock (2). The
transcription factor nuclear factor (NF)-B is thought to be
one of the central regulators of this process (3). NF-B is
composed of homo- and heterodimers of the Rel family pro-
teins, such as p65 and p50. NF-B is held in an inactive form
in the cytoplasm by association with members of the IB
family. Phosphorylation and degradation of IB in response
to LPS leads to NF-B translocation into the nucleus (3, 4).
NF-B activation plays an indispensable role in inducing the
rapid production of TNF- (3). This cytokine in turn activates
a second level of inflammatory cascades, leading to vascular
instability andmicrovascular occlusion thatmight contribute
to septic multiple organ failure (3). Therefore, NF-B and
TNF- have widely been proposed as therapeutic targets in
critical care medicine (3, 5–8), and safe, efficient, and specific
inhibitory compounds are urgently searched for. The car-
diovascular peptide, atrial natriuretic peptide (ANP), repre-
sents a promising candidate because it has been shown in
vitro that the peptide inhibits both activation of NF-B and
TNF- production in mouse macrophages (9, 10).
ANP belongs to a family of structurally related 22–53-
amino acid peptides, which display broad and disparate
effects in the cardiovascular system (11). Importantly, ANP
(international non-proprietary name: carperitide, HANP) is
in fact approved as a drug in Japan for the treatment of acute
heart failure (12). Notably, we and others demonstrated that
natriuretic peptide (NP) biology is not restricted to cardio-
vascular functions but is linked to the immune system. NPs,
especially ANP and their receptors, are expressed and reg-
ulated in immune cells (13). Moreover, both ANP and ANP
receptors are regulated by inflammatory stimuli, suggesting
NPs as regulatory proteins in inflammatory processes (13,
14). ANP is not only regulated by proinflammatory factors
but also exerts antiinflammatory action on isolated macro-
phages as well as on endothelial cells interfering with the
MAPK network as well as with proinflammatory transcrip-
tion factors, such as NF-B and activating protein-1 (9, 15,
16). However, until now, the in vivo relevance of this mech-
anistic work onANPhas not been examined. Here, we report
that administration of ANP potently abrogates LPS-induced
NF-B activation and prevents increased TNF- serum con-
centration and thereby improves survival of mice exposed to
bacterial LPSs.
Materials and Methods
Animal model
Male pyrogen-free BALB/cmice (20–30 g)were injectedwith LPS [2.5
mg/kg body weight (BW) Salmonella abortus equi S.; Bioclot, Aidenbach,
Germany]. Mice were treated with either ANP (5 g/kg BW iv; Bachem,
Heidelberg, Germany). ANP dosage is based on preliminary dose curve
experiments measuring effects on TNF- serum concentration) or NaCl
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solution (0.9%) 15 min before LPS challenge. Survival of mice was
monitored for at least 72 h. In another set of experiments, organ and
blood samples were obtained after lethal iv anesthesia (pentobarbital,
Sanofi-Ceva, Du¨sseldorf, Germany; 0.8 mg/kg BW heparin, Braun, Mel-
sungen, Germany) at different time points (15, 30, 90 min) and imme-
diately snap-frozen in liquid nitrogen. Blood was withdrawn by cardiac
puncture. Animal experiments have been performed with the permis-
sion of the government authorities and in accordance with the German
legislation on Laboratory Animal Experiments. All studies followed the
directives of the University of Konstanz Ethical Committee.
TNF- measurement
Serum and tissue TNF- levels were determined by ELISA using an
OptEIAMouse-Specific TNF-ELISA Set (mono/mono; BDBiosciences,
Heidelberg, Germany).
For TNF- mRNA expression, total RNA contents were extracted
using the RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany) ac-
cording to the manufacturer’s instruction manual. Real-time RT-PCR
was performed with the Dynamo Probe 2-Step qRT-PCR Kit
(Finnzymes; New England Biolabs, Espoo, Finland). The following
primers and probes (Biomers, Ulm, Germany) have been used: TNF-
forward (400 nm), 5-TGG CCT CCC TCT CAT CAG TTC-3; TNF-
reverse (400 nm), 5-TTG GTG GTT TGC TAC GAC GTG-3 (bp 1–1561;
GenBank accession no. NM 013693); TNF- TaqMan probe (100 nm),
5-FAM-TGG CCC AGA CCC TCA CAC TCA GAT CAT C-BHQ-3;
hypoxanthine phosphoribosyltranferase (HPRT)1 forward, 5-GTT
AAG CAG TAC AGC CCC AAA ATG-3; HPRT1 reverse, 5-AAA TCC
AAC AAA GTC TGG CCT GTA-3 (bp 1–1261; GenBank accession no.
NM 013556); and HPRT1 TaqMan probe, 5-HEX-AGC TTG CTG GTG
AAAAGGACC TCT CGAAGT-BHQ-3. HPRTwas used as an internal
housekeeping gene. Calculation of themRNAcontentwas performed by
a mathematical model developed by Pfaffl (17).
DNA binding of NF-B: EMSA analysis
Tissue was homogenized (Potter S, B. Braun Biotech) in buffer A [10
mm HEPES (pH 7.9), 10 mm KCl, 0.1 mm EDTA, 0.1 mm EGTA, 1 mm
dithiothreitol, 0.5 mm phenylmethylsulfonylfluoride (PMSF)], centri-
fuged, and further incubated (4 C, 10 min) in buffer A containing 10%
NP-40. Probes were centrifuged, the supernatant was discarded, and the
remaining pellet was suspended in buffer B [20 mmHEPES (pH 7.9), 0.4
mmNaCl, 1 mm EDTA, 1 mm EGTA, 20% glycerol, 1 mm dithiothreitol,
0.1 mm PMSF]. Samples were kept at 4 C for 30 min while continuously
shaking. After centrifugation, supernatants were frozen at80 C. EMSA
was performed as described previously (18). The consensus binding
sequence used for NF-B was 5-AGT TGA GGG GAC TTT CCC AGG
C-3 (Promega, Mannheim, Germany). Specificity of the protein-DNA
complex was confirmed by adding a 100-fold excess of unlabeled NF-B
or activating protein-1 (5-CGC TTG ATG AGT CAG CCG GAA-3)
binding sequences.
Western blot
Liver tissue (20–60mg)was homogenized (Potter S, B. Braun Biotech)
in 200–600 l lysis buffer [50 mmHEPES, 50 mmNaCl, 5 mm EDTA, 10
mmNaPyroP, 50 mmNaF, 1 mm PMSF, 1 mmNa-vanadate (pH 7.0), 1%
Triton X-100, 1Complete]. After centrifugation, samples were used for
protein quantification by use of the Pierce assay (BC assay reagents;
Interdim, Montluc¸on, France). Proteins were separated by electrophore-
sis and subsequently transferred to a polyvinylidene difluoride mem-
brane (Immobilon-P; Millipore, Bedford, MA). Proteins were identified
by incubating the membrane with primary antibody [IB-, Santa Cruz,
Heidelberg, Germany; IB- phospho (Ser32/Ser36), Akt phospho
(Ser473), Akt, Cell Signaling, Frankfurt/Main, Germany; at 4 C over-
night], followed by incubation with an horseradish peroxidase-conju-
gated secondary antibody (goat antirabbit; Dianova, Hamburg, Ger-
many). The reactive bands were visualized employing a
chemiluminescent detection kit (ECL Plus; Amersham Pharmacia, Upp-
sala, Sweden).
Statistical analysis
Animal experiments were performed using the number of animals as
shown in the respective figure legend. Results are shown asmean sem.
Statistical analysis as indicated was performed using GraphPad Prism
3.03 software (GraphPad Software Inc., SanDiego, CA). Significancewas
calculated at the 95% confidence interval in comparison with its corre-
sponding control experiment, unless indicated otherwise.
Results
ANP improves survival of mice challenged with LPS
Administration of LPS (2.5 mg/kg BW) alone caused mor-
tality of all mice within 24 h. In contrast, 75% of the animals
receiving ANP (5 g/kg BW) 15 min before lethal LPS in-
jection survived (Fig. 1A).
ANP prevents LPS-induced increase of serum TNF- level
TNF- concentration in blood is an important marker in
LPS-induced shock. Ninety minutes after LPS injection, LPS-
induced TNF- serum levels were reduced by 88% in ANP-
pretreated mice compared with control mice (Fig. 1B). Ad-
ministration of ANP alone did not affect TNF-
concentration (data not shown).
ANP decreases TNF- tissue expression
Examining various tissues for effects of ANP on TNF-
synthesis revealed that spleen and even more pronounced
FIG. 1. A, ANP pretreatment reduces mortality in LPS-challenged
mice. Animals were pretreated with ANP (5 g/kg BW) for 15 min
before LPS (2.5 mg/kg BW) injection. NaCl as well as solely ANP
administrationwere used for control. The animal’s state of healthwas
continuously observed for 72 h. Eight animals were analyzed for each
treatment group. Graph displays survival rate in percentage of con-
trol mice (*), ANP-treatedmice (Œ), LPS-treatedmice (-  -), and ANP-
preconditioned LPS-treated mice (---). B, ANP prevents increase of
serum TNF- levels in LPS-treated mice. Animals were treated as
mentioned under A. After 90 min of LPS injection, blood was with-
drawn from the heart and used for TNF- (concentration) determi-
nation by ELISA. Statistical analysis was performed by data evalu-
ation using the unpaired Student’s t test, implicating analysis of
means  SEM. *, P  0.05.
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liver show a rapid (after 30 min) decrease of LPS-induced
TNF- gene expression afterANPpretreatment (Fig. 2, C and
D). ANP injection as such did not alter basal TNF- expres-
sion (data not shown). TNF-mRNA expression in heart and
lung was not affected by ANP (Fig. 2, A and B). TNF-
protein concentrationwas reduced in lung (by 32 9%), liver
(by 34  15%), and spleen (70  11%) in ANP-pretreated
animals compared with LPS-challenged animals (90 min).
Impact of ANP on the transcription factor NF-B
The transcription factor NF-B is one of the most impor-
tant players within the LPS-induced signaling cascade, fi-
nally leading to TNF- expression. As shown in Fig. 3, en-
dotoxemia immediately led to highly increased NF-B
binding activity, detectable as soon as 15 min after LPS in-
jection in whole-liver homogenates. NF-B binding activity
has not been detectable in NaCl (control)-treated mice, and
ANP injection alone does not influence NF-B activation.
Notably, preconditioning with the cardiovascular hormone
ANP provoked a strong decrease of NF-B binding activity
at both 15 and 30 min past LPS injection. This effect points
to ANP being able to modulate one of the key parameters
involved in early inflammatory signaling pathways.
Mechanisms leading to decreased NF-B binding activity
Effects of ANP on phosphorylation and degradation of
NF-B inhibitory factor IB-, as well as on activation of the
protein kinase Akt, in livers of LPS-treated mice were ex-
amined. Both proteins are known to be involved in LPS-
mediated NF-B activation.
As shown in Fig. 4A, increased IB- phosphorylation and
decreased levels of total IB- were clearly detected 30 min
after LPS injection. Importantly, ANP pretreatment abro-
gated LPS-induced IB- phosphorylation as early as after 15
min comparedwith LPS-treated animals. An increase of total
protein contents of IB-was not seen within the first 30 min
in LPS- and ANP-treated livers. LPS administration led also
to a significant increase in Akt phosphorylation in mouse
liver after 30 min (Fig. 4B). ANP preconditioning clearly
decreased this Akt phosphorylation. Interestingly, pretreat-
ment of mice with wortmannin (16 g/kg), a common phos-
phatidylinositol 3-kinase inhibitor that leads to inhibition of
Akt phosphorylation, also decreased TNF- serum level in
LPS-treated mice although not as potently as ANP pretreat-
ment (42  14% vs. 88  4%).
FIG. 2. ANP pretreatment modulates TNF- mRNA expression in
different organs derived from LPS-treated mice. Animals were pre-
treated with ANP (5 g/kg BW) as described in Fig. 1. NaCl admin-
istration was used for control experiments. Organ samples were ob-
tained 30 min after LPS injection. Whole-organ homogenates were
analyzed by real-time RT-PCR. Graphs are displaying TNF-mRNA
expression in heart (A), lung (B), spleen (C), and liver (D). Four
animals were analyzed for each treatment group. Statistical analysis
was made by evaluation of these data using the unpaired Student’s
t test, implicating analysis of means  SEM. *, P  0.05.
FIG. 3. ANP pretreatment reduces LPS-induced NF-B binding ac-
tivity in liver homogenates. Animals were pretreated with ANP (5
g/kg BW) 15 min before LPS injection. Mice exclusively receiving
NaCl (control) or ANP were also examined. Organ samples were
obtained 15 and 30 min after LPS injection. For investigations of
NF-B binding activity, whole-liver homogenates were analyzed by
EMSA. EMSA assays were performed in duplicate.
FIG. 4. ANP pretreatment reduces LPS-induced IB- phosphoryla-
tion, IB- degradation, and Akt phosphorylation in liver. Animals
were pretreated with ANP (5 g/kg BW) 15 min before LPS injection
(2.5 mg/kg BW). Mice receiving NaCl (control) or ANP were addi-
tionally examined. Liver was excised 15 and 30 min after LPS injec-
tion. IB- phosphorylation (pIB) and IB- total protein contents
(totIB) (A) and Akt phosphorylation (pAkt) as well as Akt total
protein contents (totAkt) (B) were determined by Western blot anal-
ysis. Representative blots of six independent experiments are shown.
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Discussion
This work profiles the cardiovascular peptide ANP as a
potent regulator protein of NF-B activation and, consecu-
tively, TNF- production in vivo. Pretreatment of mice with
ANP resulted in improved survival of mice after LPS chal-
lenge. Although various in vitro data indicate an antiinflam-
matory profile of ANP, this is the first report of a potent in
vivo antiinflammatory action of this peptide hormone, which
is approved as a drug for acute heart failure.
We showed that ANP early and efficiently targets NF-B
activation, a central molecular event leading to the devel-
opment of the systemic inflammatory response syndrome
(3). NF-B is activated by a variety of bacteria and bacterial
components and is a common denominator of a plethora of
shock-inducing agents. Studies using animal models of sys-
temic inflammation have shown that NF-B activity is mark-
edly elevated in multiple organs (3, 19, 20). NF-B activity is
also strongly increased in patients with septic shock, and the
degree of NF-B activity correlates with the severity of the
disease (19, 21). Greater NF-B activity is associated with
higher rates of mortality and worse clinical outcome. NF-B
activation mediates the transcriptional expression of a large
number of proinflammatory proteins, such as TNF-, which
play important roles in the pathophysiology of systemic in-
flammation. Mice deficient in those NF-B-dependent genes
are resistant to the development of septic shock and sepsis-
related death in endotoxin models (22, 23). Therefore, effi-
cient inhibitors of NF-B are searched for urgently. Along
this line, IB- gene transfer strategies either overexpressing
a dominant-negative or a wild-type isoform of IB- have
turned out to be beneficial in in vivo animal studies (19).
However, the application of systemic NF-B inhibitors using
genetic approaches faces problems such as feasibility, safety,
and efficacy, which have yet to be overcome. Other known
NF-B inhibitors include proteasome inhibitors, glucocorti-
coids, nonsteroidal antiinflammatory drugs, antiinflamma-
tory cytokines, and various natural products. However, they
also face problems regarding their therapeutical application
because efficacy, but also known (and unknown) side effects
will limit their clinical use (3, 8). In this respect, ANP, being
an endogenous peptide and approved as a drug for acute
myocardial failure, has some advantages. The dose necessary
to block NF-B in our model is well within the limits of
therapeutic doses given in case of acute heart failure (12, 24).
However, because it is known that during septic shock severe
hypotension is prevalent, the effect of ANP on blood pres-
sure may be a limiting factor in the treatment. On the other
hand, the usefulness of ANP may be analogous to its ben-
eficial effect in the treatment of heart failure, which is a
clinical situation with increased ANP.
Importantly, ANP pretreatment affects the LPS-induced
NF-B/TNF- pathways at a rather upstream stage. These
are important features regarding the therapeutic outcome.
Transcriptional activation of NF-B in LPS-challenged indi-
viduals results in a rapid release of TNF- into the circulation
and although reduction of TNF- plasma levels leads to
improved survival in a murine LPS-induced shock (25), anti-
TNF- strategies failed to prevent death in septic patients
(26). This fact is probably related more to the difficulty of
designing clinical trials in these patients rather than to the
scientific rationale. Anti-TNF- therapy requires a prophy-
lactic treatment to prevent the deleterious secondary inflam-
matory responses. Because we did not examine whether
ANP will also lead to reduced TNF- level when given
simultaneously or even after LPS application to the peptide,
we are not really able to comment on its role for the inter-
vention in human septic shock patients. However, because of
the distinct prevention of the increase of TNF- serum levels
by ANP, the peptide at least might exert considerable anti-
inflammatory action in humans.
Regarding the underlying signaling pathway, ANP is
shown to abrogate LPS-induced phosphorylation of IB-
and consecutively its degradation. ANP affects another tar-
get discussed in the pathology of sepsis, namely Akt. LPS
exposure either of animals or patients leads to an increase of
phosphorylated Akt that could even be predictive for the
clinical outcome (21). ANP inhibits the LPS-induced activa-
tion of Akt. Akt is known to phosphorylate p65 and thereby
to increase its transcriptional activity (27). ANP may inhibit
NF-B not only by inhibiting nuclear translocation of p65 but
also via inhibition of its transcriptional activity. In fact, we
observed reduced TNF- levels by employing wortmannin,
a PI3 kinase inhibitor that reduces Akt activity.
It is important to mention that inhibition of Akt is a two-
edged sword effect and asks for caution regarding its general
therapeutical use. Besides its proposed role in sepsis, Akt is
discussed to promote tumor progression through increased
cell survival. However, the protein Akt has recently been
shown to be also closely implicated in the blockade of cancer
cell motility and metastasis (28).
Our data do not only point to a potential therapeutic use
of ANP as an antiinflammatory drug but also prompt the
question about the role of the endogenous ANP system in
sepsis. Until now, pro-ANP concentrations are used as reli-
able diagnostic and prognostic tools in the management of
congestive heart failure and recently also of severe sepsis (29,
30) and discussed as a consequence of left ventricular systolic
dysfunction. However, it has also been shown that immune
cells such as macrophages but also endothelial cells secrete
increased levels of NPs upon challenge with LPS (13, 14).
Furthermore, ANP has been shown to inhibit inflammatory
mediators such as inducible nitric oxide synthase via an
autocrine mechanism (10). Thus, elevated ANP levels in sep-
sis might also function as an endogenous regulator of
inflammation.
In summary, the data presented here show that ANP, a
cardiovascular hormone used as a drug against heart failure,
possesses potent antiinflammatory actions in vivo. Because
ANP targets early NF-B activation upon LPS challenge, we
propose to consider this factor for intervention therapy strat-
egies in systemic inflammation.
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